Arrowhead Research Corporation (ARWR)

Price$73.09

Value ScoreD

Growth ScoreC

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)30.77%

Price vs S&P 500 (4W)0.56%

VGM Score51.72

Market Capitalization$10.30B

All Metrics

P/CF (Annual)57.34x

Book Value / Share (Quarterly)$4.37

P/TBV (Annual)10.19x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)50.52%

Cash Flow / Share (Quarterly)$-0.36

Price vs S&P 500 (YTD)1.93%

Net Profit Margin (TTM)-48.38%

EPS (TTM)$-2.15

10-Day Avg Trading Volume1.49M

EPS Excl Extra (TTM)$-2.15

Revenue Growth (5Y)56.63%

EPS (Annual)$-0.01

ROI (Annual)-0.15%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-3428.42%

Cash / Share (Quarterly)$12.68

P/E Basic Excl Extra (TTM)50.32x

Revenue Growth QoQ (YoY)-86.41%

ROA (Last FY)-0.12%

Revenue Growth TTM (YoY)14.09%

EBITD / Share (TTM)$-1.40

ROE (5Y Avg)-95.58%

Operating Margin (TTM)-35.67%

Cash Flow / Share (Annual)$1.16

P/B Ratio16.77x

P/B Ratio (Quarterly)14.30x

Net Income / Employee (Annual)$-2,300

EV / Revenue (TTM)18.29x

Net Interest Coverage (TTM)1.99x

ROA (TTM)-18.13%

EV / EBITDA (TTM)34.93x

EPS Incl Extra (Annual)$-0.01

Current Ratio (Annual)4.86x

Quick Ratio (Quarterly)6.16x

3-Month Avg Trading Volume2.37M

52-Week Price Return344.05%

EV / Free Cash Flow (Annual)72.50x

P/E Incl Extra (TTM)50.32x

Revenue / Employee (TTM)$874,800

Tangible BV / Share (Quarterly)$4.33

P/S Ratio (Annual)12.41x

Asset Turnover (Annual)0.60x

52-Week High$82.26

Operating Margin (5Y Avg)-3436.30%

EPS Excl Extra (Annual)$-0.01

CapEx CAGR (5Y)13.56%

Tangible BV CAGR (5Y)0.57%

26-Week Price Return38.69%

Quick Ratio (Annual)4.81x

13-Week Price Return14.92%

Total Debt / Equity (Annual)1.34x

Current Ratio (Quarterly)6.23x

Enterprise Value$11.37B

Revenue / Share Growth (5Y)47.98%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)-5.30%

Revenue / Employee (Annual)$1,166,600

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)6.21%

Cash / Share (Annual)$6.76

3-Month Return Std Dev55.24%

Net Income / Employee (TTM)$-423,200

ROE (Last FY)-0.35%

Net Interest Coverage (Annual)-3.80x

EPS Basic Excl Extra (Annual)$-0.01

P/FCF (TTM)96.93x

Receivables Turnover (TTM)68.92x

EV / Free Cash Flow (TTM)32.79x

Total Debt / Equity (Quarterly)2.06x

EPS Incl Extra (TTM)$-2.15

Receivables Turnover (Annual)343.86x

ROI (TTM)-22.98%

P/S Ratio (TTM)16.55x

Pretax Margin (5Y Avg)-3499.99%

Revenue / Share (Annual)$6.20

Tangible BV / Share (Annual)$3.38

Price vs S&P 500 (52W)319.68%

P/E Ratio (TTM)50.32x

Year-to-Date Return10.09%

5-Day Price Return-2.81%

EPS Normalized (Annual)$-0.01

ROA (5Y Avg)-24.96%

Net Profit Margin (Annual)-0.20%

Month-to-Date Return-6.19%

Cash Flow / Share (TTM)$-1.62

EBITD / Share (Annual)$0.91

Operating Margin (Annual)11.86%

LT Debt / Equity (Annual)1.25x

P/CF (TTM)30.00x

ROI (5Y Avg)-43.92%

P/E Excl Extra (TTM)50.32x

LT Debt / Equity (Quarterly)2.00x

EPS Basic Excl Extra (TTM)$-2.15

P/TBV (Quarterly)14.44x

P/B Ratio (Annual)10.04x

Pretax Margin (TTM)-40.56%

Book Value / Share (Annual)$3.43

Price vs S&P 500 (13W)6.67%

Beta1.29x

P/FCF (Annual)65.62x

Revenue / Share (TTM)$4.37

ROE (TTM)-55.45%

52-Week Low$14.30

vGradeD

gGradeC

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q2 26-0.93est. -1.21

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.95

4.00

4.05

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARWRArrowhead Research Corporation	D	C	A	$73.09
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Arrowhead Pharmaceuticals is a biotechnology company developing genetic medicines to treat diseases caused by protein overproduction. Its pipeline spans cardiovascular, cardiometabolic, pulmonary, central nervous system, liver, muscular, and complement-mediated disease areas, with the majority of its product candidates concentrated in liver disease treatments.